Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has entered into two new relationships with Inex Pharmaceuticals and the Massachusetts Institute of Technology providing access to key technologies for the systemic delivery of RNAi therapeutics.
Subscribe to our email newsletter
The agreement with Inex Pharmaceuticals provides access to fundamental liposome delivery technology for systemic RNAi therapeutics.
The agreement with the Massachusetts Institute of Technology (MIT) provides access to novel liposome technology being developed in the laboratory of Professor Robert Langer.
Alnylam recently announced the publication in the scientific journal Nature of the first demonstration of therapeutic gene silencing in primates with systemic RNAi using liposomal delivery technology.
“By taking advantage of the leadership of each company in its respective field, we expect this relationship to significantly accelerate the development of truly novel drugs for important diseases,” said Timothy Ruane, president and CEO of Inex.